Locations:
Search IconSearch
January 28, 2019/Digestive/Research

Can a Swallowable Capsule Revolutionize Screening for Barrett’s Esophagus?

Trial aimed at improving outcomes for patients with BE and esophageal cancer now open

650x450_Barretts_Esophagus

Although the rate of many common cancers has declined, the incidence of esophageal adenocarcinoma has increased greater than six-fold over the past three decades. Furthermore, the outcome of this cancer remains poor, accounting for over 1 in 50 adult male cancer-related deaths.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Barrett’s esophagus (BE), a precursor of esophageal cancer, can be easily recognized at endoscopy; however, current clinical strategies of endoscopic screening and surveillance based on the close association of BE with chronic gastroesophageal reflux disease (GERD) in adults are woefully inadequate. Despite endoscopic screening and surveillance efforts, less than 5 percent of esophageal cancers are diagnosed in individuals with previously detected BE.

The National Institutes of Health is funding a multicenter clinical trial aimed at improving outcomes for patients with BE and esophageal cancer. Prashanthi Thota, MD, Director for Center of Swallowing & Motility Disorders at Cleveland Clinic, and study collaborators at different academic centers are testing whether a swallowable capsule can gather a sample and assay methylated DNA biomarkers to diagnose BE and esophageal cancer.

Inclusion criteria

Adult white males with GERD for five years or longer are the group at the highest risk for BE and esophageal cancer, which is reflected in the study’s inclusion criteria. The study is trying to recruit subjects who have not had prior EGD and are:

  • Male gender
  • White race
  • Age > 40 < 85
  • GERD > 5 years
  • No prior EGD

OR have GERD > 5 years, Age > 40 < 85, and No prior EGD PLUS at least three of the following criteria:

  • Male gender
  • White race
  • Obesity (BMI > 30)
  • History of smoking
  • Family history – two family members with reported BE or esophageal cancer

If you have a patient who could benefit from this clinical trial, please email Dr. Thota at thotap@ccf.org or call at 216.444.0780.

Advertisement

Related Articles

Physician speaking with patient
June 17, 2025/Digestive/Research
Inconsistent Personality Test Responses Associated with Bariatric Surgery Revisions

Retrospective study highlights psychosocial predictors of bariatric surgery outcomes

Physician speaking with patient
May 20, 2025/Digestive/Research
Luminal GI Cancers Driving the Rise in Early-Onset GI Cancer Rates

Greater awareness among young patients is needed

Physician with RFA device
May 19, 2025/Digestive/Research
New Approach Reduces Mortality, Complications in Malignant Biliary Obstruction

Combining RFA with stenting improves survival rates, reduces post-ERCP complications

Dr. Liska speaking with researcher
May 14, 2025/Digestive/Research
Rectal Cancer Patients with IBD Do Not Respond as Well to Neoadjuvant Therapy

Poor response may be due to different tumor biology

Dr. Gorgun in surgery
May 13, 2025/Digestive/Research
Rectal Cancer: Local Regrowth After TNT Does Not Increase Risk of Distant Metastasis

Study sheds light on distant metastasis rates between upfront surgery and Watch & Wait strategies

Dr. Holubar in surgery
May 12, 2025/Digestive/Research
New Study Highlights LMWH's Role in Lowering VTE Incidence After IBD Surgery

Findings help close the knowledge gap around VTE practice patterns

Blood being drawn
May 6, 2025/Digestive/Research
Study Suggests Non-Biopsy Diagnosis May Be Accurate for a Select Group of Adults with Celiac Disease

Potential for non-invasive methods to transform adult celiac disease diagnoses

Ad